Bone safety of dual-release hydrocortisone in patients with hypopituitarism

Endocrine. 2018 Jun;60(3):528-531. doi: 10.1007/s12020-017-1512-1. Epub 2018 Jan 8.

Authors

Stefano Frara¹, Sabrina Chiloiro², Teresa Porcelli³, Antonella Giampietro², Gherardo Mazziotti⁴, Laura De Marinis², Andrea Giustina⁵

Affiliations

¹ Chair of Endocrinology, Università Vita-Salute San Raffaele, Milan, Italy.
² Pituitary Unit, Catholic University of the Sacred Heart, Rome, Italy.
³ Montichiari Hospital, ASST Spedali Civili of Brescia, Brescia, Italy.
⁴ Endocrine Unit, ASST Carlo Poma, Mantua, Italy.
⁵ Chair of Endocrinology, Università Vita-Salute San Raffaele, Milan, Italy. giustina.andrea@hsr.it.

PMID: 29313195
DOI: 10.1007/s12020-017-1512-1

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Hydrocortisone / adverse effects*
Hydrocortisone / therapeutic use
Hypopituitarism / drug therapy*
Male
Middle Aged
Osteoporosis / chemically induced*

Substances

Hydrocortisone